Altaris Capital Partners Acquires Perrigo's Prescription Pharmaceuticals Business (Padagis)

Altaris Capital Partners Acquires Meridian Medical Technologies from Pfizer

December 30, 2021

Medical Devices

Altaris Capital Partners has entered into an agreement to acquire Meridian Medical Technologies from Pfizer. Meridian, a pioneer in emergency response drug-device combination products and auto-injectors with facilities in St. Louis, Missouri and Columbia, Maryland and more than 750 employees, will become an Altaris portfolio company to expand the firm's capabilities in medical countermeasures and emergency response solutions.

Altaris Capital Partners Acquires Kindeva Drug Delivery from 3M

May 1, 2020

Medical Devices

Altaris Capital Partners has acquired Kindeva Drug Delivery L.P. (formerly 3M Drug Delivery Systems) from 3M Company for $650 million in a corporate carve-out transaction. Monroe Capital provided financing and an equity co-investment to support the deal, and 3M will retain a minority interest alongside Altaris as Kindeva operates independently to pursue growth and capital investments.

Altaris Acquires 51% Stake in Solesis from Michelin

June 1, 2021

Medical Devices

Altaris Capital Partners has completed the acquisition of a 51% stake in Solesis from Michelin, with Michelin retaining a 49% ownership interest and partnering with Altaris to build Solesis as an independent company. Solesis, a U.S.-based biomaterials and medical-device components manufacturer operating through The Secant Group, Charter Medical and SanaVita Medical, employs approximately 360 people across production facilities in Pennsylvania and North Carolina.

Altaris Acquires Tegria Services Group from Providence St. Joseph Health

January 6, 2026

Healthcare Services

Altaris has completed the acquisition of Tegria Services Group, Inc. from Providence St. Joseph Health, establishing Tegria as a standalone, Altaris‑backed portfolio company that will continue to serve Providence as a preferred technology services partner. The deal positions Altaris to expand its healthcare services and technology platform capabilities—supporting providers and payers with consulting, managed services, data & analytics, and revenue cycle management.

Olympus Partners Acquires PAI Pharma

February 24, 2025

Pharmaceuticals

Olympus Partners has acquired PAI Pharma, a leading U.S. developer, manufacturer and distributor of generic oral liquid medicines. The platform was previously owned by Enhanced Healthcare Partners and Bourne Partners Strategic Capital; terms were not disclosed and Monroe Capital provided senior financing for the deal.

Kindeva Drug Delivery (Altaris) Acquires Summit Biosciences

January 18, 2024

Medical Devices

Kindeva Drug Delivery, an operating company of healthcare investor Altaris, has acquired Summit Biosciences from its founding family shareholders. The acquisition adds Summit’s FDA- and EMA-approved 55,000 sq. ft. cGMP intranasal CDMO facility in Lexington, Kentucky, expanding Kindeva’s nasal drug‑delivery platform and global manufacturing footprint.